NDAVAGINALCREAM
Approved
Nov 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8
Data completeness
3/8 — Basic
GYNE-LOTRIMIN 3 (clotrimazole) by Bayer is clinical pharmacology clotrimazole is a broad-spectrum antifungal agent that is used for the treatment of dermal infections caused by various species of pathogenic dermatophytes, yeasts, and malassezia furfur . First approved in 1998.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GYNE-LOTRIMIN 3 is a vaginal cream formulation of clotrimazole, a broad-spectrum antifungal agent used to treat vaginal yeast infections caused by Candida species. It works by disrupting fungal cell membrane integrity, causing leakage of intracellular contents and cell death. The drug exhibits both fungistatic and fungicidal activity with minimal systemic absorption when applied topically.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential workforce consolidation or transition planning on brand teams.
Mechanism of Action
CLINICAL PHARMACOLOGY Clotrimazole is a broad-spectrum antifungal agent that is used for the treatment of dermal infections caused by various species of pathogenic dermatophytes, yeasts, and Malassezia furfur . The primary action of clotrimzole is against dividing and growing organisms. In vitro ,…
Worked on GYNE-LOTRIMIN 3 at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.